Reversal of neuromuscular block with a selective relaxant-binding agent: Sugammadex

American Journal of Therapeutics

Volumn 16, Issue 4, 2009, Pages 295-299

  Ren, Wendy H P ^a   Jahr, Jonathan S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acetylcholine; Acetylcholinesterase inhibitor; Antagonist; Antimuscarinic; Clearance; Cyclodextrin; Depolarizing; Elimination; Neuromuscular blocker; Nondepolarizing; Pharmacokinetics; Rocuronium; Succhinylcholine; Sugammadex; Volume of distribution

Indexed keywords

CHOLINESTERASE INHIBITOR; CYCLODEXTRIN DERIVATIVE; EDROPHONIUM; MOXIFLOXACIN; MUSCARINIC RECEPTOR BLOCKING AGENT; NEOSTIGMINE; ROCURONIUM; SUGAMMADEX; SUXAMETHONIUM; VECURONIUM;

ALBUMIN BLOOD LEVEL; ANESTHESIA; ARTICLE; BINDING AFFINITY; CLINICAL PRACTICE; CLINICAL TRIAL; COUGHING; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; GLOMERULUS FILTRATION RATE; GRIMACE; HUMAN; NEUROMUSCULAR BLOCKING; PRIORITY JOURNAL; SIDE EFFECT; SUCKING;

ANDROSTANOLS; ANESTHESIA; GAMMA-CYCLODEXTRINS; HUMANS; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR DISEASES; NEUROMUSCULAR NONDEPOLARIZING AGENTS; VECURONIUM BROMIDE;

EID: 68949184613     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31817fe2d7     Document Type: Article

References (21)

1. Stoelting RK. Neuromuscular blocking drugs. In: Stoelting RK, ed. Pharmacology & Physiology in Anesthetic Practice. Philadelphia, PA: Churchill Livingstone; 2006: 208-250.
2. Naguib M, Lien CA. Pharmacology of muscle relaxants and their antagonists. In: Miller RD, ed. Miller's Anesthesiology. Vol 6. Elsevier; Orlando, FL: 2005:481-572.
3. Gronert GA. Cardiac arrest after succinylcholine. Anesthesiology. 2001;94:523-529.
4. Van den brock L, Proost JH, Wierda JMKH. Early and late reversibility of rocuronium bromide. Eur J Anaesthesiol Suppl. 1994;9:128-132.
5. Kopman AF, Yee P, Neuman GG. Relationship of the train-of-four fade ratio to clinical signs and symptoms of residual paralysis in awake volunteers. Anesthesiology. 1997;86:765-771.
6. Bevan DR, Francois D, Kopman AF. Reversal of neuromuscular blockade. Anesthesiology. 1992;77:785-805.
7. Briefing Document for the Anesthesia and Life Support Drug Advisory Committee Meeting. Bridion® NDA 22-225. March 11, 2008. Department of Health & Human Services Food & Drug Administration Center for Drug Evaluation & Research Division of Anesthesia, Analgesia and Rheumatology Products. Available at: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4346b1-01- FDA.pdf. Accessed May 16, 2008.
8. Gitlin M, Jahr JS, Margolis MA, et al. Is mivacurium chloride effective in electroconvulsive therapy? A report of four cases, including a patient with myasthenia gravis. Anesth Analg. 1993;77:392-394.
9. Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg. 2007;104: 575-581.
10. Bom A, Bradley M, Cameron K, et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl. 2002;41:266-270.
11. Kopman AF. Sugammadex: a revolutionary approach to neuromuscular antagonism [editorial]. Anesthesiology. 2006;104:631-633.
12. Gijsenbergh F, Ramael S, Houwing N, et al. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology. 2005;103:695-703.
13. Epemolu O, Bom A, Hope F, et al. Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology. 2003;99:632-637.
14. Sparr HJ, Vermeyen KM, Beaufort AM, et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study. Anesthesiology. 2007;106:935-943.
15. Lee C, Jahr JS, Candiotti K, et al. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparision with spontaneous recovery from succinylcholine. Anesthesiology. 2009; 110:1020-1025.
16. Sacan O, Shite PF, Tufanogullari B, et al. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine. Anesth Analg. 2007;104:569-574.
17. Jones KR, Caldwell JE, Brull SJ, et al. Faster reversal of profound rocuronium-induced neuromuscular blockade with sugammadex vs neostigmine. Anesthesiology. 2007; 107:A1577.
18. Groudine SB, Soto R, Lien C, et al. A randomized, dose-finding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg. 2007;104:555-562.
19. McDonagh DL, Benedict PE, Kovac AL, et al. Efficacy and safety of sugammadex for reversal of rocuronium-induced blockade in elderly patients. Anesthesiology. 2007; 107:A1583.
20. de Kam P, van Kuijk J, Smeets J, et al. Single IV sugammadex doses up to 32 mg/kg are not associated with QT/QTc prolongation. Anesthesiology. 2007;07:A1580.
21. Dahl V, Pendeville PE, Hollman MW, et al. Reversal of rocuronium-induced neuromuscular blockade by sugammadex in cardiac patients. Anesthesiology. 2007; 107:A1581.